Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients

RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before

First in ASH 2018 Series

by David Wallace

Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018.  Discussing Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys combo therapy in Patients with Myelofibrosis.


 

 
error: Content is protected !